Vaccine Adverse Event Reporting System | Centers for Disease Control and Prevention |
---|---|
FDA takes additional action in fight against COVID-19 by issuing emergency use authorization for second COVID-19 vaccine | mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-Cov-2 variants |
Interim considerations for COVID-19 vaccination of healthcare personnel and long-term care facility residents.
2Phased allocation of COVID-19 vaccines | Centers for Disease Control and Prevention |
---|---|
Centers for Disease Control and Prevention | COVID-19 vaccines vs variants — Determining how much immunity is enough |
Vaccination considerations for persons with underlying medication conditions.
12Centers for Disease Control and Prevention | Centers for Disease Control and Prevention |
---|---|
When vaccine is limited, who should get vaccinated first? Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera | Centers for Disease Control and Prevention |
Centers for Disease Control and Prevention.
18